Acalabrutinib

Description

Acalabrutinib is a small-molecule inhibitor of BTK (Bruton’s tyrosine kinase). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. In nonclinical studies, acalabrutinib inhibited BTK-mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and tumor growth in mouse xenograft models.

Medicine classification

ATC Code
Title
Class
Acalabrutinib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EL Bruton's tyrosine kinase (BTK) inhibitors

Medicines

Drug
Countries

Australia Austria Canada France Hong Kong

Product monographs

Monograph
Type
Country
MPI, US: SPL/PLR
US

2D Molecule Structure

2D representation of molecule

Unique Ingredient Identifier (UNII)

I42748ELQW - ACALABRUTINIB

SNOMED-CT

763037006 - Acalabrutinib (substance)